CONGRESSES
CONGRESSES
Find information on previous and upcoming congresses
View upcoming congresses and filter through abstracts, presentations, and posters from past congresses.
Upcoming congresses
Mid-Atlantic Allergy Conference
BioCryst will attend the 2026 Mid-Atlantic Allergy Conference from May 15 – May 17, 2026.
Browse our archive of congress materials
Filter
Showing 131 Materials
-
Long-Term, Sustained, Robust Hereditary Angioedema Attack Suppression with Navenibart Administered Every 3 and 6 Months: ALPHA-SOLAR Interim Results
AAAAI | 2026 | HAE -
Navenibart Demonstrates Durable Efficacy and Tolerability Across Biological Sexes: Subgroup Analysis from the ALPHA-STAR Trial
AAAAI | 2026 | HAE -
Navenibart Delays Time to First Attack in Hereditary Angioedema: Results from ALPHA-STAR
AAAAI | 2026 | HAE -
Real-World Attack Rate Reductions After Berotralstat Initiation Among Patients with Hereditary Angioedema with Normal C1-Inhibitor Stratified by Prior Long-Term Prophylaxis
AAAAI | 2026 | HAE -
Impact of Berotralstat on Hereditary Angioedema Attack Rates in Patients with C1-Inhibitor Deficiency: Real-World Evidence Stratified by Prior Long-Term Prophylaxis
AAAAI | 2026 | HAE -
Impact of Berotralstat on Healthcare Resource Utilization in Patients with Hereditary Angioedema\ with Normal C1-Inhibitor
AAAAI | 2026 | HAE -
Reductions in Healthcare Resource Utilization Among Patients with Hereditary Angioedema with C1-Inhibitor Deficiency Following the Initiation of Berotralstat
AAAAI | 2026 | HAE -
Medication Routines Among Patients With Hereditary Angioedema
AAAAI | 2026 | HAE -
Oral Berotralstat Reduces the Rate of Moderate and Severe Attacks and Percentage of Days with HAE Symptoms Over 48 Weeks in Children Aged 2 to Less Than 12 Years: Interim Data from APeX-P
AAAAI | 2026 | HAE -
Oral Berotralstat Reduces Hereditary Angioedema Attack Rates in Pediatric Patients Aged 2 to <12 Years Without Long-Term Prophylaxis During the 12-Week Standard of Care Period: Interim Data from the APeX-P Study
WSAAI | 2026 | HAE